Pfizer vs Roche

Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine

Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine

Investor Presentation Released: Pfizer

AI parsed presentation narrative: Pfizer is demonstrating steady execution and financial outperformance by exceeding revenue and EPS expectations despite the decline in COVID-19 product sales. Management's central thesis focuses on maximizing the value of key acquisitions like Seagen and Metsera to drive post-2028 growth through a high single-digit revenue CAGR and a robust pipeline in oncology and obesity. Key tailwinds mentioned: Acquisition Integration Success, Obesity Pipeline Advancement.

Non-endemic brands target Amazon via retail media

Kiri Masters requested her Amazon advertising data and discovered nearly 400 advertiser audiences that included many non-endemic brands (banks, insurers, airlines, streaming services). The piece argues retail media networks (RMNs) are increasingly attractive to advertisers that do not sell on the retailer, driven by harder-to-access consumer data elsewhere, DSPs expanding offsite reach (notably Amazon DSP), and improved measurement (e.g., Amazon Marketing Cloud). Examples cited include Home Depot’s Orange Apron Media beta with Pinterest, Kroger running Chevrolet’s Equinox EV via Yahoo DSP, and Dick’s Sporting Goods exploring financial-services partnerships. Industry sources and forecasts (eMarketer, IAB, academic commentary) are used to frame this as a structural growth opportunity for sophisticated RMNs able to service non-endemic demand.

• Kiri Masters requested her Amazon consumer ad data and found an 'AdvertiserAudiences' file listing nearly 400 companies including Pfizer, GEICO, Emirates Airlines, Chase, McDonald’s and Westpac.
• Amazon recorded 42 conversion events for the author between June 19 and August 5, with Emirates appearing 18 times.
• eMarketer projects US offsite retail media ad spending will reach $17.05bn in 2026, up 29.5% year over year.

Roche and Ypsomed Stay Top in Swiss Reputation Ranking

Swissreputation Group and Pressrelations Schweiz analyzed nearly 90,000 reputation-relevant statements from about 4,000 Swiss online and print sources using an AI-supported method to evaluate media reputation for 40 pharma and medtech companies. The study measured presence (coverage and reach) and tonality (positive/negative reporting) and calculated a Reputation Score (0–100) for each company across six reputation dimensions. In Pharma & Biopharma, Roche ranks first (ahead of MSD, Novartis, Sandoz and AstraZeneca). In MedTech & Diagnostics, Ypsomed remains first (ahead of Medacta, Straumann Group, Alcon and Sonova). The study notes products/services, innovation and economic performance tended to improve media reputation, while workplace issues (layoffs, relocations) and ESG/legal problems harmed reputation. The article was published on 2026-08-13.

• Swissreputation Group and Pressrelations Schweiz analyzed nearly 90,000 reputation-relevant statements from about 4,000 Swiss online and print sources using an AI-supported method.
• The study measured presence and tonality for 40 pharma and medtech companies and computed a Reputation Score between 0 and 100 across six reputation dimensions.
• In the Pharma & Biopharma category, Roche ranked first, followed by MSD, Novartis, Sandoz and AstraZeneca.

Roche Pharma Day 2026 announced

Roche Pharma Day 2026 will be held on Monday, 28th September 2026, 09:00am BST. More details available via the investor update.

Investor Presentation Released: Roche

AI parsed presentation narrative: Roche is successfully transitioning to a post-pandemic growth phase, with base business growth of 7% and core operating profit expanding faster than sales. The strategy focuses on maximizing high-growth franchises like Vabysmo and Ocrevus while aggressively expanding into the obesity market and AI-driven diagnostics. Strategic pillars: Maximizing value of existing growth drivers, Leading in Obesity and Metabolic disease.